Abbvie and Mitsubishi Tanabe Pharma participated in the RNA therapy startup's first round through their corporate venturing units.

US-based biotechnology startup Ribometrix has secured $7.5m in a seed round that included Abbvie Ventures and MP Healthcare Venture Management, respective subsidiaries of pharmaceutical companies Abbvie and Mitsubishi Tanabe Pharma.

SV Health Investors and Hatteras Venture Partners co-led the round, which also featured Dementia Discovery Fund and Alexandria Venture Investments, the strategic investment arm of life sciences real estate investment trust Alexandria Real Estate Equities. RNA drug developer Moderna invested $100,000, according to ExitEvent.

Founded in 2015, Ribometrix is developing…